analysis_id,n_persons,person_days,n_events,incidence_start_date,incidence_end_date,person_years,incidence_100000_pys,incidence_100000_pys_95CI_lower,incidence_100000_pys_95CI_upper,cohort_obscured,result_obscured,outcome_cohort_id,outcome_cohort_name,analysis_repeated_events,analysis_interval,analysis_complete_database_intervals,denominator_cohort_id,analysis_outcome_washout,analysis_min_cell_count,denominator_cohort_name,denominator_age_group,denominator_sex,denominator_days_prior_observation,denominator_start_date,denominator_end_date,denominator_target_cohort_definition_id,denominator_target_cohort_name,cdm_name,result_type
1,539,339334,0,2017-01-02,2022-06-30T00:00:00Z,929.0458590006845,0,0,397.0610727528379,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,1,NA,5,Denominator cohort 1,0 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
10,70,29377,0,2017-01-03,2022-06-30T00:00:00Z,80.42984257357973,0,0,4586.456141250349,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,13,NA,5,Denominator cohort 13,18 to 29,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
100,84,21334,0,2017-01-06,2022-06-30T00:00:00Z,58.40930869267625,0,0,6315.567735141628,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,121,NA,5,Denominator cohort 121,18 to 29,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
101,31,7672,0,2017-01-06,2022-06-30T00:00:00Z,21.00479123887748,0,0,17562.08577444102,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,122,NA,5,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
102,53,13662,0,2017-01-06,2022-03-31T00:00:00Z,37.40451745379877,0,0,9862.122826929548,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,123,NA,5,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
103,109,29071,0,2017-01-12,2022-06-30T00:00:00Z,79.59206023271732,0,0,4634.732966238226,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,124,NA,5,Denominator cohort 124,30 to 39,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
104,47,12731,0,2017-01-20,2022-05-17T00:00:00Z,34.85557837097878,0,0,10583.325902247387,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,125,NA,5,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
105,62,16340,0,2017-01-12,2022-06-30T00:00:00Z,44.73648186173853,0,0,8245.796943788953,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,126,NA,5,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
106,148,37491,0,2017-01-10,2022-06-30T00:00:00Z,102.64476386036961,0,0,3593.8311077728385,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,127,NA,5,Denominator cohort 127,40 to 49,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
107,72,17568,0,2017-01-10,2022-05-04T00:00:00Z,48.09856262833676,0,0,7669.417239384761,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,128,NA,5,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
108,76,19923,0,2017-01-10,2022-06-30T00:00:00Z,54.54620123203286,0,0,6762.853087462305,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,129,NA,5,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
109,178,46775,0,2017-01-03,2022-03-31T00:00:00Z,128.06297056810405,0,0,2880.5199799361085,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,130,NA,5,Denominator cohort 130,50 to 59,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
11,32,14117,0,2017-01-03,2022-03-31T00:00:00Z,38.65023956194388,0,0,9544.260257952219,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,14,NA,5,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
110,78,21549,0,2017-01-03,2022-03-31T00:00:00Z,58.997946611909654,0,0,6252.555666690403,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,131,NA,5,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
111,100,25226,0,2017-01-03,2022-03-31T00:00:00Z,69.06502395619438,0,0,5341.168717256462,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,132,NA,5,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
112,186,51975,0,2017-01-07,2022-06-30T00:00:00Z,142.29979466119096,0,0,2592.32942879291,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,133,NA,5,Denominator cohort 133,60 to 69,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
113,83,23444,0,2017-01-09,2022-06-30T00:00:00Z,64.18617385352498,0,0,5747.155863398375,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,134,NA,5,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
114,103,28531,0,2017-01-07,2022-06-30T00:00:00Z,78.11362080766598,0,0,4722.453543917546,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,135,NA,5,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
115,114,33028,0,2017-01-04,2022-06-30T00:00:00Z,90.42573579739904,0,0,4079.457492476429,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,136,NA,5,Denominator cohort 136,70 to 79,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
116,50,14690,0,2017-02-28,2022-06-30T00:00:00Z,40.219028062970565,0,0,9171.97563386736,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,137,NA,5,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
117,64,18338,0,2017-01-04,2022-04-05T00:00:00Z,50.20670773442848,0,0,7347.383687507443,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,138,NA,5,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
118,57,18196,0,2017-01-04,2022-03-31T00:00:00Z,49.817932922655714,0,0,7404.722030199576,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,139,NA,5,Denominator cohort 139,80 to 89,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
119,20,6083,0,2017-01-04,2022-03-31T00:00:00Z,16.654346338124572,0,0,22149.65018272423,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,140,NA,5,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
12,38,15260,0,2017-01-11,2022-06-30T00:00:00Z,41.779603011635864,0,0,8829.378903113466,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,15,NA,5,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
120,37,12113,0,2017-01-16,2022-03-31T00:00:00Z,33.163586584531146,0,0,11123.282594032155,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,141,NA,5,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
121,209,140123,0,2017-01-03,2022-06-30T00:00:00Z,383.63586584531146,0,0,961.557503489873,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,145,NA,5,Denominator cohort 145,0 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
122,86,50933,0,2017-01-17,2022-06-30T00:00:00Z,139.4469541409993,0,0,2645.363949924636,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,146,NA,5,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
123,123,89190,0,2017-01-03,2022-06-30T00:00:00Z,244.18891170431212,0,0,1510.6662412996018,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,147,NA,5,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
124,NA,NA,0,2020-01-23,2021-10-31T00:00:00Z,NA,0,0,207926.42293443132,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,154,NA,5,Denominator cohort 154,13 to 17,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
125,NA,NA,0,2020-01-23,2021-10-31T00:00:00Z,NA,0,0,207926.42293443132,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,156,NA,5,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
126,7,2171,0,2017-02-10,2021-12-31T00:00:00Z,5.943874058863792,0,0,62061.87105550966,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,157,NA,5,Denominator cohort 157,18 to 29,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
127,5,1501,0,2017-02-10,2021-12-31T00:00:00Z,4.1095140314852845,0,0,89764.37179314555,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,158,NA,5,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
128,NA,NA,0,2017-02-21,2018-12-31T00:00:00Z,NA,0,0,201098.9881515097,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,159,NA,5,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
129,23,13396,0,2017-01-12,2022-03-31T00:00:00Z,36.67624914442163,0,0,10057.951781241525,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,160,NA,5,Denominator cohort 160,30 to 39,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
13,95,42001,0,2017-01-02,2022-06-30T00:00:00Z,114.99247091033538,0,0,3207.9312888148256,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,16,NA,5,Denominator cohort 16,30 to 39,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
130,9,3075,0,2017-01-20,2022-03-31T00:00:00Z,8.41889117043121,0,0,43816.69010130455,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,161,NA,5,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
131,14,10321,0,2017-01-12,2022-03-31T00:00:00Z,28.257357973990416,0,0,13054.580182299342,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,162,NA,5,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
132,35,17195,0,2017-01-04,2022-06-30T00:00:00Z,47.07734428473648,0,0,7835.784941059115,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,163,NA,5,Denominator cohort 163,40 to 49,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
133,18,9370,0,2017-01-27,2022-06-30T00:00:00Z,25.65366187542779,0,0,14379.54344306419,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,164,NA,5,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
134,17,7825,0,2017-01-04,2022-06-30T00:00:00Z,21.423682409308693,0,0,17218.699304985494,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,165,NA,5,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
135,52,25593,0,2017-01-10,2022-06-30T00:00:00Z,70.06981519507187,0,0,5264.57711333222,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,166,NA,5,Denominator cohort 166,50 to 59,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
136,22,9902,0,2017-01-18,2022-06-30T00:00:00Z,27.110198494182068,0,0,13606.980616189809,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,167,NA,5,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
137,30,15691,0,2017-01-10,2022-03-31T00:00:00Z,42.959616700889804,0,0,8586.85374173166,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,168,NA,5,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
138,50,27546,0,2017-01-03,2022-06-30T00:00:00Z,75.41683778234086,0,0,4891.320774759002,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,169,NA,5,Denominator cohort 169,60 to 69,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
139,18,7358,0,2017-02-03,2022-03-31T00:00:00Z,20.145106091718002,0,0,18311.54145984119,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,170,NA,5,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
14,41,13735,0,2017-01-03,2022-06-30T00:00:00Z,37.60438056125941,0,0,9809.706739098032,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,17,NA,5,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
140,32,20188,0,2017-01-03,2022-06-30T00:00:00Z,55.27173169062286,0,0,6674.079753393675,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,171,NA,5,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
141,30,25132,0,2017-01-04,2022-06-30T00:00:00Z,68.80766598220397,0,0,5361.146031414591,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,172,NA,5,Denominator cohort 172,70 to 79,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
142,11,9058,0,2017-01-17,2022-06-30T00:00:00Z,24.799452429842574,0,0,14874.842356095327,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,173,NA,5,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
143,19,16074,0,2017-01-04,2022-03-31T00:00:00Z,44.0082135523614,0,0,8382.252212362293,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,174,NA,5,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
144,11,11928,0,2017-01-03,2022-03-31T00:00:00Z,32.6570841889117,0,0,11295.801648349388,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,175,NA,5,Denominator cohort 175,80 to 89,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
145,NA,NA,0,2017-06-22,2022-03-31T00:00:00Z,NA,0,0,50143.77449256103,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,176,NA,5,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
146,8,9241,0,2017-01-03,2022-03-31T00:00:00Z,25.300479123887747,0,0,14580.27508511108,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,177,NA,5,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
147,209,60743,0,2017-01-03,2022-06-30T00:00:00Z,166.30527036276524,0,0,2218.137432486237,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,181,NA,5,Denominator cohort 181,0 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
148,86,24309,0,2017-01-17,2022-03-31T00:00:00Z,66.55441478439425,0,0,5542.651777593133,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,182,NA,5,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
149,123,36434,0,2017-01-03,2022-06-30T00:00:00Z,99.75085557837097,0,0,3698.093046646306,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,183,NA,5,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
15,54,28266,0,2017-01-02,2022-06-30T00:00:00Z,77.38809034907598,0,0,4766.727590090974,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,18,NA,5,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
150,NA,NA,0,2020-01-23,2021-01-22T00:00:00Z,NA,0,0,368132.0274904686,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,190,NA,5,Denominator cohort 190,13 to 17,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
151,NA,NA,0,2020-01-23,2021-01-22T00:00:00Z,NA,0,0,368132.0274904686,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,192,NA,5,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
152,7,1217,0,2017-02-10,2021-12-31T00:00:00Z,3.3319644079397674,0,0,110711.85050247452,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,193,NA,5,Denominator cohort 193,18 to 29,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
153,5,812,0,2017-02-10,2021-12-31T00:00:00Z,2.223134839151266,0,0,165931.43111023583,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,194,NA,5,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
154,NA,NA,0,2017-02-21,2018-04-10T00:00:00Z,NA,0,0,332682.2766950901,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,195,NA,5,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
155,23,6915,0,2017-01-12,2021-12-01T00:00:00Z,18.93223819301848,0,0,19484.64527281439,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,196,NA,5,Denominator cohort 196,30 to 39,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
156,9,2435,0,2017-01-20,2021-12-01T00:00:00Z,6.666666666666667,0,0,55333.191811709024,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,197,NA,5,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
157,14,4480,0,2017-01-12,2020-09-19T00:00:00Z,12.265571526351813,0,0,30075.071888730243,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,198,NA,5,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
158,35,8474,0,2017-01-04,2022-03-31T00:00:00Z,23.200547570157426,0,0,15899.967201028026,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,199,NA,5,Denominator cohort 199,40 to 49,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
159,18,4490,0,2017-01-27,2022-03-31T00:00:00Z,12.292950034223136,0,0,30008.08954599365,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,200,NA,5,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
16,83,39407,0,2017-01-02,2022-06-30T00:00:00Z,107.89048596851471,0,0,3419.096151991055,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,19,NA,5,Denominator cohort 19,40 to 49,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
160,17,3984,0,2017-01-04,2022-03-31T00:00:00Z,10.907597535934292,0,0,33819.357947166536,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,201,NA,5,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
161,52,13466,0,2017-01-10,2022-03-31T00:00:00Z,36.86789869952088,0,0,10005.667760397406,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,202,NA,5,Denominator cohort 202,50 to 59,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
162,22,5756,0,2017-01-18,2022-03-31T00:00:00Z,15.759069130732374,0,0,23407.97812048497,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,203,NA,5,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
163,30,7710,0,2017-01-10,2022-03-31T00:00:00Z,21.1088295687885,0,0,17475.52815324403,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,204,NA,5,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
164,50,14419,0,2017-01-03,2022-06-30T00:00:00Z,39.47707049965777,0,0,9344.359668597786,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,205,NA,5,Denominator cohort 205,60 to 69,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
165,18,4784,0,2017-02-03,2022-03-31T00:00:00Z,13.097878165639973,0,0,28163.946919212267,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,206,NA,5,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
166,32,9635,0,2017-01-03,2022-06-30T00:00:00Z,26.379192334017795,0,0,13984.05003233124,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,207,NA,5,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
167,30,9329,0,2017-01-04,2022-03-31T00:00:00Z,25.541409993155373,0,0,14442.740064477597,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,208,NA,5,Denominator cohort 208,70 to 79,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
168,11,3186,0,2017-01-17,2022-02-22T00:00:00Z,8.722792607802875,0,0,42290.119918867385,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,209,NA,5,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
169,19,6143,0,2017-01-04,2022-03-31T00:00:00Z,16.8186173853525,0,0,21933.30979350667,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,210,NA,5,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
17,33,15995,0,2017-01-02,2022-06-30T00:00:00Z,43.79192334017796,0,0,8423.652520257048,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,20,NA,5,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
170,11,3353,0,2017-01-03,2022-03-31T00:00:00Z,9.180013689253936,0,0,40183.812126904704,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,211,NA,5,Denominator cohort 211,80 to 89,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
171,NA,NA,0,2017-06-22,2022-03-31T00:00:00Z,NA,0,0,176819.3202906975,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,212,NA,5,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
172,8,2591,0,2017-01-03,2021-09-12T00:00:00Z,7.093771389459275,0,0,52001.66810556213,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,213,NA,5,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
173,539,339334,0,2017-01-02,2022-06-30T00:00:00Z,929.0458590006845,0,0,397.0610727528379,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,1,NA,5,Denominator cohort 1,0 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
174,233,144645,0,2017-01-02,2022-06-30T00:00:00Z,396.01642710472277,0,0,931.496574796996,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,2,NA,5,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
175,306,194689,0,2017-01-02,2022-06-30T00:00:00Z,533.0294318959617,0,0,692.0592435192101,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,3,NA,5,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
176,8,3585,0,2017-01-26,2022-03-31T00:00:00Z,9.815195071868583,0,0,37583.353434173354,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,7,NA,5,Denominator cohort 7,3 to 12,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
177,NA,NA,0,2018-06-21,2020-12-31T00:00:00Z,NA,0,0,68290.07707121718,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,8,NA,5,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
178,NA,NA,0,2017-01-26,2022-03-31T00:00:00Z,NA,0,0,83583.32634088802,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,9,NA,5,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
179,16,7397,0,2017-01-09,2020-12-31T00:00:00Z,20.251882272416154,0,0,18214.995547047653,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,10,NA,5,Denominator cohort 10,13 to 17,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
18,50,23412,0,2017-01-12,2022-06-30T00:00:00Z,64.09856262833675,0,0,5755.011193469652,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,21,NA,5,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
180,11,5256,0,2017-01-09,2020-12-31T00:00:00Z,14.390143737166325,0,0,25634.764471368242,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,11,NA,5,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
181,5,2141,0,2017-01-19,2019-05-31T00:00:00Z,5.861738535249829,0,0,62931.49092083675,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,12,NA,5,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
182,70,29377,0,2017-01-03,2022-06-30T00:00:00Z,80.42984257357973,0,0,4586.456141250349,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,13,NA,5,Denominator cohort 13,18 to 29,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
183,32,14117,0,2017-01-03,2022-03-31T00:00:00Z,38.65023956194388,0,0,9544.260257952219,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,14,NA,5,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
184,38,15260,0,2017-01-11,2022-06-30T00:00:00Z,41.779603011635864,0,0,8829.378903113466,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,15,NA,5,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
185,95,42001,0,2017-01-02,2022-06-30T00:00:00Z,114.99247091033538,0,0,3207.9312888148256,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,16,NA,5,Denominator cohort 16,30 to 39,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
186,41,13735,0,2017-01-03,2022-06-30T00:00:00Z,37.60438056125941,0,0,9809.706739098032,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,17,NA,5,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
187,54,28266,0,2017-01-02,2022-06-30T00:00:00Z,77.38809034907598,0,0,4766.727590090974,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,18,NA,5,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
188,83,39407,0,2017-01-02,2022-06-30T00:00:00Z,107.89048596851471,0,0,3419.096151991055,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,19,NA,5,Denominator cohort 19,40 to 49,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
189,33,15995,0,2017-01-02,2022-06-30T00:00:00Z,43.79192334017796,0,0,8423.652520257048,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,20,NA,5,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
19,84,49184,0,2017-01-04,2022-06-30T00:00:00Z,134.65845311430527,0,0,2739.4340041784217,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,22,NA,5,Denominator cohort 22,50 to 59,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
190,50,23412,0,2017-01-12,2022-06-30T00:00:00Z,64.09856262833675,0,0,5755.011193469652,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,21,NA,5,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
191,84,49184,0,2017-01-04,2022-06-30T00:00:00Z,134.65845311430527,0,0,2739.4340041784217,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,22,NA,5,Denominator cohort 22,50 to 59,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
192,35,19380,0,2017-01-04,2022-03-31T00:00:00Z,53.059548254620125,0,0,6952.338599665195,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,23,NA,5,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
193,49,29804,0,2017-01-04,2022-06-30T00:00:00Z,81.59890485968515,0,0,4520.746277731562,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,24,NA,5,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
194,89,40784,0,2017-01-03,2022-06-30T00:00:00Z,111.66050650239562,0,0,3303.656386365032,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,25,NA,5,Denominator cohort 25,60 to 69,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
195,37,17864,0,2017-01-09,2022-06-30T00:00:00Z,48.90896646132786,0,0,7542.337777737993,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,26,NA,5,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
196,52,22920,0,2017-01-03,2022-06-30T00:00:00Z,62.75154004106776,0,0,5878.54808296298,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,27,NA,5,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
197,60,48148,0,2017-01-03,2022-06-30T00:00:00Z,131.82203969883642,0,0,2798.3783762879348,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,28,NA,5,Denominator cohort 28,70 to 79,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
198,26,22417,0,2017-01-24,2022-06-30T00:00:00Z,61.374401095140314,0,0,6010.452873333251,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,29,NA,5,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
199,34,25731,0,2017-01-03,2022-06-30T00:00:00Z,70.44763860369609,0,0,5236.342235494598,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,30,NA,5,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
2,233,144645,0,2017-01-02,2022-06-30T00:00:00Z,396.01642710472277,0,0,931.496574796996,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,2,NA,5,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
20,35,19380,0,2017-01-04,2022-03-31T00:00:00Z,53.059548254620125,0,0,6952.338599665195,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,23,NA,5,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
200,34,24362,0,2017-01-04,2022-06-30T00:00:00Z,66.69952087611225,0,0,5530.593631947768,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,31,NA,5,Denominator cohort 31,80 to 89,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
201,14,8447,0,2017-01-04,2022-06-30T00:00:00Z,23.12662559890486,0,0,15950.789873506747,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,32,NA,5,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
202,20,15915,0,2017-01-10,2022-06-30T00:00:00Z,43.572895277207394,0,0,8465.99573116629,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,33,NA,5,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
203,539,146372,0,2017-01-02,2022-06-30T00:00:00Z,400.7446954140999,0,0,920.5061218095776,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,37,NA,5,Denominator cohort 37,0 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
204,233,63291,0,2017-01-02,2022-06-30T00:00:00Z,173.28131416837783,0,0,2128.83857201674,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,38,NA,5,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
205,306,83081,0,2017-01-02,2022-06-30T00:00:00Z,227.4633812457221,0,0,1621.746513180047,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,39,NA,5,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
206,8,2126,0,2017-01-26,2022-03-31T00:00:00Z,5.820670773442847,0,0,63375.504262234936,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,43,NA,5,Denominator cohort 43,3 to 12,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
207,NA,NA,0,2018-06-21,2020-04-30T00:00:00Z,NA,0,0,100624.58705116615,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,44,NA,5,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
208,NA,NA,0,2017-01-26,2022-03-31T00:00:00Z,NA,0,0,171202.44226367408,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,45,NA,5,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
209,16,4882,0,2017-01-09,2019-10-23T00:00:00Z,13.366187542778919,0,0,27598.591163767207,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,46,NA,5,Denominator cohort 46,13 to 17,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
21,49,29804,0,2017-01-04,2022-06-30T00:00:00Z,81.59890485968515,0,0,4520.746277731562,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,24,NA,5,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
210,11,3116,0,2017-01-09,2019-10-23T00:00:00Z,8.531143052703628,0,0,43240.15470523475,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,47,NA,5,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
211,5,1766,0,2017-01-19,2019-04-16T00:00:00Z,4.8350444900752905,0,0,76294.63310391364,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,48,NA,5,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
212,70,16988,0,2017-01-03,2022-03-31T00:00:00Z,46.510609171800134,0,0,7931.264543295944,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,49,NA,5,Denominator cohort 49,18 to 29,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
213,32,8079,0,2017-01-03,2022-03-31T00:00:00Z,22.119096509240247,0,0,16677.35141249059,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,50,NA,5,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
214,38,8909,0,2017-01-11,2022-03-31T00:00:00Z,24.39151266255989,0,0,15123.619043833369,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,51,NA,5,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
215,95,22431,0,2017-01-02,2022-06-30T00:00:00Z,61.412731006160165,0,0,6006.701531876041,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,52,NA,5,Denominator cohort 52,30 to 39,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
216,41,9528,0,2017-01-03,2022-06-30T00:00:00Z,26.086242299794662,0,0,14141.091736094824,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,53,NA,5,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
217,54,12903,0,2017-01-02,2022-06-30T00:00:00Z,35.3264887063655,0,0,10442.247699101876,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,54,NA,5,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
218,83,19819,0,2017-01-02,2022-06-30T00:00:00Z,54.261464750171115,0,0,6798.341089939528,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,55,NA,5,Denominator cohort 55,40 to 49,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
219,33,7809,0,2017-01-02,2022-06-30T00:00:00Z,21.37987679671458,0,0,17253.979006468366,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,56,NA,5,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
22,89,40784,0,2017-01-03,2022-06-30T00:00:00Z,111.66050650239562,0,0,3303.656386365032,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,25,NA,5,Denominator cohort 25,60 to 69,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
220,50,12010,0,2017-01-12,2022-06-30T00:00:00Z,32.88158795345654,0,0,11218.67794017581,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,57,NA,5,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
221,84,23572,0,2017-01-04,2022-03-31T00:00:00Z,64.5366187542779,0,0,5715.947822056316,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,58,NA,5,Denominator cohort 58,50 to 59,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
222,35,9282,0,2017-01-04,2022-03-31T00:00:00Z,25.412731006160165,0,0,14515.871801498759,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,59,NA,5,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
223,49,14290,0,2017-01-04,2022-03-31T00:00:00Z,39.123887748117724,0,0,9428.713930126767,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,60,NA,5,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
224,89,24312,0,2017-01-03,2022-06-30T00:00:00Z,66.56262833675565,0,0,5541.967837344171,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,61,NA,5,Denominator cohort 61,60 to 69,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
225,37,10827,0,2017-01-09,2022-06-30T00:00:00Z,29.642710472279262,0,0,12444.474190589404,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,62,NA,5,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
226,52,13485,0,2017-01-03,2022-06-30T00:00:00Z,36.91991786447639,0,0,9991.570045347533,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,63,NA,5,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
227,60,17441,0,2017-01-03,2022-06-30T00:00:00Z,47.75085557837098,0,0,7725.263577863166,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,64,NA,5,Denominator cohort 64,70 to 79,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
228,26,7112,0,2017-01-24,2022-06-30T00:00:00Z,19.471594798083505,0,0,18944.927174003304,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,65,NA,5,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
229,34,10329,0,2017-01-03,2022-03-31T00:00:00Z,28.279260780287473,0,0,13044.469170443557,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,66,NA,5,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
23,37,17864,0,2017-01-09,2022-06-30T00:00:00Z,48.90896646132786,0,0,7542.337777737993,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,26,NA,5,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
230,34,9335,0,2017-01-04,2022-06-30T00:00:00Z,25.557837097878167,0,0,14433.457103536313,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,67,NA,5,Denominator cohort 67,80 to 89,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
231,14,3400,0,2017-01-04,2022-03-31T00:00:00Z,9.308692676249144,0,0,39628.33001809161,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,68,NA,5,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
232,20,5935,0,2017-01-10,2022-06-30T00:00:00Z,16.249144421629023,0,0,22701.991922748355,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,69,NA,5,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
233,894,569032,0,2017-01-03,2022-06-30T00:00:00Z,1557.924709103354,0,0,236.78162574602393,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,73,NA,5,Denominator cohort 73,0 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
234,387,240226,0,2017-01-03,2022-06-30T00:00:00Z,657.7029431895961,0,0,560.8731863391619,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,74,NA,5,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
235,507,328806,0,2017-01-03,2022-06-30T00:00:00Z,900.2217659137577,0,0,409.77452376632874,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,75,NA,5,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
236,5,1078,0,2017-01-26,2019-12-31T00:00:00Z,2.951403148528405,0,0,124987.31174537243,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,79,NA,5,Denominator cohort 79,3 to 12,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
237,NA,NA,0,2017-01-30,2017-01-31T00:00:00Z,NA,0,0,67368161.03075574,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,80,NA,5,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
238,NA,NA,0,2017-01-26,2019-12-31T00:00:00Z,NA,0,0,125219.63016869097,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,81,NA,5,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
239,13,6984,0,2017-02-16,2022-03-31T00:00:00Z,19.121149897330596,0,0,19292.14233412249,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,82,NA,5,Denominator cohort 82,13 to 17,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
24,52,22920,0,2017-01-03,2022-06-30T00:00:00Z,62.75154004106776,0,0,5878.54808296298,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,27,NA,5,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
240,5,2738,0,2017-08-03,2021-12-31T00:00:00Z,7.496235455167693,0,0,49209.75970106337,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,83,NA,5,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
241,8,4246,0,2017-02-16,2022-03-31T00:00:00Z,11.624914442162902,0,0,31732.529924990933,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,84,NA,5,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
242,84,38353,0,2017-01-06,2022-06-30T00:00:00Z,105.00479123887749,0,0,3513.0582239071646,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,85,NA,5,Denominator cohort 85,18 to 29,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
243,31,12361,0,2017-01-06,2022-06-30T00:00:00Z,33.842573579739906,0,0,10900.115044212562,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,86,NA,5,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
244,53,25992,0,2017-01-06,2022-06-30T00:00:00Z,71.16221765913758,0,0,5183.76123659247,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,87,NA,5,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
245,109,51587,0,2017-01-12,2022-06-30T00:00:00Z,141.2375085557837,0,0,2611.8270506428266,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,88,NA,5,Denominator cohort 88,30 to 39,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
246,47,19299,0,2017-01-20,2022-06-30T00:00:00Z,52.837782340862425,0,0,6981.518320198534,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,89,NA,5,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
247,62,32288,0,2017-01-12,2022-06-30T00:00:00Z,88.39972621492129,0,0,4172.953483074563,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,90,NA,5,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
248,148,70692,0,2017-01-10,2022-06-30T00:00:00Z,193.5441478439425,0,0,1905.962797226157,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,91,NA,5,Denominator cohort 91,40 to 49,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
249,72,29461,0,2017-01-10,2022-06-30T00:00:00Z,80.65982203969884,0,0,4573.379113455466,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,92,NA,5,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
25,60,48148,0,2017-01-03,2022-06-30T00:00:00Z,131.82203969883642,0,0,2798.3783762879348,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,28,NA,5,Denominator cohort 28,70 to 79,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
250,76,41231,0,2017-01-10,2022-06-30T00:00:00Z,112.88432580424367,0,0,3267.8402673112823,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,93,NA,5,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
251,178,83367,0,2017-01-03,2022-06-30T00:00:00Z,228.24640657084188,0,0,1616.1829268356964,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,94,NA,5,Denominator cohort 94,50 to 59,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
252,78,36939,0,2017-01-03,2022-06-30T00:00:00Z,101.13347022587268,0,0,3647.535722718847,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,95,NA,5,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
253,100,46428,0,2017-01-03,2022-06-30T00:00:00Z,127.1129363449692,0,0,2902.048808079424,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,96,NA,5,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
254,186,111914,0,2017-01-07,2022-06-30T00:00:00Z,306.403832991102,0,0,1203.9273197411537,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,97,NA,5,Denominator cohort 97,60 to 69,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
255,83,47998,0,2017-01-09,2022-06-30T00:00:00Z,131.4113620807666,0,0,2807.1236731012023,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,98,NA,5,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
256,103,63916,0,2017-01-07,2022-06-30T00:00:00Z,174.99247091033538,0,0,2108.0218108378417,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,99,NA,5,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
257,114,78936,0,2017-01-04,2022-06-30T00:00:00Z,216.11498973305956,0,0,1706.9058738916526,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,100,NA,5,Denominator cohort 100,70 to 79,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
258,50,37846,0,2017-02-28,2022-06-30T00:00:00Z,103.6167008898015,0,0,3560.120542765721,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,101,NA,5,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
259,64,41090,0,2017-01-04,2022-06-30T00:00:00Z,112.49828884325804,0,0,3279.053834546398,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,102,NA,5,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
26,26,22417,0,2017-01-24,2022-06-30T00:00:00Z,61.374401095140314,0,0,6010.452873333251,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,29,NA,5,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
260,57,50262,0,2017-01-04,2022-06-30T00:00:00Z,137.6098562628337,0,0,2680.6796797085567,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,103,NA,5,Denominator cohort 103,80 to 89,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
261,20,17590,0,2017-01-04,2022-06-30T00:00:00Z,48.158795345653665,0,0,7659.825017709578,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,104,NA,5,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
262,37,32672,0,2017-01-16,2022-03-31T00:00:00Z,89.45106091718002,0,0,4123.907996495822,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,105,NA,5,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
263,894,250767,0,2017-01-03,2022-06-30T00:00:00Z,686.5626283367557,0,0,537.2968614750405,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,109,NA,5,Denominator cohort 109,0 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
264,387,108405,0,2017-01-03,2022-06-30T00:00:00Z,296.79671457905545,0,0,1242.8976713390664,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,110,NA,5,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
265,507,142362,0,2017-01-03,2022-06-30T00:00:00Z,389.7659137577002,0,0,946.4345967428912,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,111,NA,5,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
266,5,947,0,2017-01-26,2019-12-31T00:00:00Z,2.5927446954141,0,0,142277.00323285267,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,115,NA,5,Denominator cohort 115,3 to 12,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
267,NA,NA,0,2017-01-30,2017-01-31T00:00:00Z,NA,0,0,67368161.03075574,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,116,NA,5,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
268,NA,NA,0,2017-01-26,2019-12-31T00:00:00Z,NA,0,0,142578.11858361005,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,117,NA,5,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
269,13,3816,0,2017-02-16,2022-03-31T00:00:00Z,10.447638603696099,0,0,35308.260498299656,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,118,NA,5,Denominator cohort 118,13 to 17,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
27,34,25731,0,2017-01-03,2022-06-30T00:00:00Z,70.44763860369609,0,0,5236.342235494598,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,30,NA,5,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
270,5,1333,0,2017-08-03,2019-11-26T00:00:00Z,3.649555099247091,0,0,101077.51092386458,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,119,NA,5,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
271,8,2483,0,2017-02-16,2022-03-31T00:00:00Z,6.798083504449007,0,0,54263.52076581212,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,120,NA,5,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
272,84,21334,0,2017-01-06,2022-06-30T00:00:00Z,58.40930869267625,0,0,6315.567735141628,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,121,NA,5,Denominator cohort 121,18 to 29,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
273,31,7672,0,2017-01-06,2022-06-30T00:00:00Z,21.00479123887748,0,0,17562.08577444102,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,122,NA,5,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
274,53,13662,0,2017-01-06,2022-03-31T00:00:00Z,37.40451745379877,0,0,9862.122826929548,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,123,NA,5,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
275,109,29071,0,2017-01-12,2022-06-30T00:00:00Z,79.59206023271732,0,0,4634.732966238226,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,124,NA,5,Denominator cohort 124,30 to 39,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
276,47,12731,0,2017-01-20,2022-05-17T00:00:00Z,34.85557837097878,0,0,10583.325902247387,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,125,NA,5,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
277,62,16340,0,2017-01-12,2022-06-30T00:00:00Z,44.73648186173853,0,0,8245.796943788953,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,126,NA,5,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
278,148,37491,0,2017-01-10,2022-06-30T00:00:00Z,102.64476386036961,0,0,3593.8311077728385,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,127,NA,5,Denominator cohort 127,40 to 49,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
279,72,17568,0,2017-01-10,2022-05-04T00:00:00Z,48.09856262833676,0,0,7669.417239384761,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,128,NA,5,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
28,34,24362,0,2017-01-04,2022-06-30T00:00:00Z,66.69952087611225,0,0,5530.593631947768,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,31,NA,5,Denominator cohort 31,80 to 89,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
280,76,19923,0,2017-01-10,2022-06-30T00:00:00Z,54.54620123203286,0,0,6762.853087462305,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,129,NA,5,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
281,178,46775,0,2017-01-03,2022-03-31T00:00:00Z,128.06297056810405,0,0,2880.5199799361085,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,130,NA,5,Denominator cohort 130,50 to 59,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
282,78,21549,0,2017-01-03,2022-03-31T00:00:00Z,58.997946611909654,0,0,6252.555666690403,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,131,NA,5,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
283,100,25226,0,2017-01-03,2022-03-31T00:00:00Z,69.06502395619438,0,0,5341.168717256462,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,132,NA,5,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
284,186,51975,0,2017-01-07,2022-06-30T00:00:00Z,142.29979466119096,0,0,2592.32942879291,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,133,NA,5,Denominator cohort 133,60 to 69,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
285,83,23444,0,2017-01-09,2022-06-30T00:00:00Z,64.18617385352498,0,0,5747.155863398375,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,134,NA,5,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
286,103,28531,0,2017-01-07,2022-06-30T00:00:00Z,78.11362080766598,0,0,4722.453543917546,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,135,NA,5,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
287,114,33028,0,2017-01-04,2022-06-30T00:00:00Z,90.42573579739904,0,0,4079.457492476429,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,136,NA,5,Denominator cohort 136,70 to 79,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
288,50,14690,0,2017-02-28,2022-06-30T00:00:00Z,40.219028062970565,0,0,9171.97563386736,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,137,NA,5,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
289,64,18338,0,2017-01-04,2022-04-05T00:00:00Z,50.20670773442848,0,0,7347.383687507443,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,138,NA,5,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
29,14,8447,0,2017-01-04,2022-06-30T00:00:00Z,23.12662559890486,0,0,15950.789873506747,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,32,NA,5,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
290,57,18196,0,2017-01-04,2022-03-31T00:00:00Z,49.817932922655714,0,0,7404.722030199576,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,139,NA,5,Denominator cohort 139,80 to 89,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
291,20,6083,0,2017-01-04,2022-03-31T00:00:00Z,16.654346338124572,0,0,22149.65018272423,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,140,NA,5,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
292,37,12113,0,2017-01-16,2022-03-31T00:00:00Z,33.163586584531146,0,0,11123.282594032155,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,141,NA,5,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
293,209,140123,0,2017-01-03,2022-06-30T00:00:00Z,383.63586584531146,0,0,961.557503489873,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,145,NA,5,Denominator cohort 145,0 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
294,86,50933,0,2017-01-17,2022-06-30T00:00:00Z,139.4469541409993,0,0,2645.363949924636,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,146,NA,5,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
295,123,89190,0,2017-01-03,2022-06-30T00:00:00Z,244.18891170431212,0,0,1510.6662412996018,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,147,NA,5,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
296,NA,NA,0,2020-01-23,2021-10-31T00:00:00Z,NA,0,0,207926.42293443132,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,154,NA,5,Denominator cohort 154,13 to 17,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
297,NA,NA,0,2020-01-23,2021-10-31T00:00:00Z,NA,0,0,207926.42293443132,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,156,NA,5,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
298,7,2171,0,2017-02-10,2021-12-31T00:00:00Z,5.943874058863792,0,0,62061.87105550966,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,157,NA,5,Denominator cohort 157,18 to 29,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
299,5,1501,0,2017-02-10,2021-12-31T00:00:00Z,4.1095140314852845,0,0,89764.37179314555,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,158,NA,5,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
3,306,194689,0,2017-01-02,2022-06-30T00:00:00Z,533.0294318959617,0,0,692.0592435192101,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,3,NA,5,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
30,20,15915,0,2017-01-10,2022-06-30T00:00:00Z,43.572895277207394,0,0,8465.99573116629,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,33,NA,5,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
300,NA,NA,0,2017-02-21,2018-12-31T00:00:00Z,NA,0,0,201098.9881515097,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,159,NA,5,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
301,23,13396,0,2017-01-12,2022-03-31T00:00:00Z,36.67624914442163,0,0,10057.951781241525,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,160,NA,5,Denominator cohort 160,30 to 39,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
302,9,3075,0,2017-01-20,2022-03-31T00:00:00Z,8.41889117043121,0,0,43816.69010130455,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,161,NA,5,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
303,14,10321,0,2017-01-12,2022-03-31T00:00:00Z,28.257357973990416,0,0,13054.580182299342,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,162,NA,5,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
304,35,17195,0,2017-01-04,2022-06-30T00:00:00Z,47.07734428473648,0,0,7835.784941059115,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,163,NA,5,Denominator cohort 163,40 to 49,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
305,18,9370,0,2017-01-27,2022-06-30T00:00:00Z,25.65366187542779,0,0,14379.54344306419,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,164,NA,5,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
306,17,7825,0,2017-01-04,2022-06-30T00:00:00Z,21.423682409308693,0,0,17218.699304985494,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,165,NA,5,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
307,52,25593,0,2017-01-10,2022-06-30T00:00:00Z,70.06981519507187,0,0,5264.57711333222,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,166,NA,5,Denominator cohort 166,50 to 59,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
308,22,9902,0,2017-01-18,2022-06-30T00:00:00Z,27.110198494182068,0,0,13606.980616189809,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,167,NA,5,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
309,30,15691,0,2017-01-10,2022-03-31T00:00:00Z,42.959616700889804,0,0,8586.85374173166,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,168,NA,5,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
31,539,146372,0,2017-01-02,2022-06-30T00:00:00Z,400.7446954140999,0,0,920.5061218095776,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,37,NA,5,Denominator cohort 37,0 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
310,50,27546,0,2017-01-03,2022-06-30T00:00:00Z,75.41683778234086,0,0,4891.320774759002,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,169,NA,5,Denominator cohort 169,60 to 69,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
311,18,7358,0,2017-02-03,2022-03-31T00:00:00Z,20.145106091718002,0,0,18311.54145984119,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,170,NA,5,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
312,32,20188,0,2017-01-03,2022-06-30T00:00:00Z,55.27173169062286,0,0,6674.079753393675,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,171,NA,5,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
313,30,25132,0,2017-01-04,2022-06-30T00:00:00Z,68.80766598220397,0,0,5361.146031414591,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,172,NA,5,Denominator cohort 172,70 to 79,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
314,11,9058,0,2017-01-17,2022-06-30T00:00:00Z,24.799452429842574,0,0,14874.842356095327,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,173,NA,5,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
315,19,16074,0,2017-01-04,2022-03-31T00:00:00Z,44.0082135523614,0,0,8382.252212362293,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,174,NA,5,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
316,11,11928,0,2017-01-03,2022-03-31T00:00:00Z,32.6570841889117,0,0,11295.801648349388,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,175,NA,5,Denominator cohort 175,80 to 89,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
317,NA,NA,0,2017-06-22,2022-03-31T00:00:00Z,NA,0,0,50143.77449256103,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,176,NA,5,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
318,8,9241,0,2017-01-03,2022-03-31T00:00:00Z,25.300479123887747,0,0,14580.27508511108,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,177,NA,5,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
319,209,60743,0,2017-01-03,2022-06-30T00:00:00Z,166.30527036276524,0,0,2218.137432486237,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,181,NA,5,Denominator cohort 181,0 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
32,233,63291,0,2017-01-02,2022-06-30T00:00:00Z,173.28131416837783,0,0,2128.83857201674,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,38,NA,5,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
320,86,24309,0,2017-01-17,2022-03-31T00:00:00Z,66.55441478439425,0,0,5542.651777593133,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,182,NA,5,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
321,123,36434,0,2017-01-03,2022-06-30T00:00:00Z,99.75085557837097,0,0,3698.093046646306,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,183,NA,5,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
322,NA,NA,0,2020-01-23,2021-01-22T00:00:00Z,NA,0,0,368132.0274904686,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,190,NA,5,Denominator cohort 190,13 to 17,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
323,NA,NA,0,2020-01-23,2021-01-22T00:00:00Z,NA,0,0,368132.0274904686,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,192,NA,5,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
324,7,1217,0,2017-02-10,2021-12-31T00:00:00Z,3.3319644079397674,0,0,110711.85050247452,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,193,NA,5,Denominator cohort 193,18 to 29,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
325,5,812,0,2017-02-10,2021-12-31T00:00:00Z,2.223134839151266,0,0,165931.43111023583,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,194,NA,5,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
326,NA,NA,0,2017-02-21,2018-04-10T00:00:00Z,NA,0,0,332682.2766950901,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,195,NA,5,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
327,23,6915,0,2017-01-12,2021-12-01T00:00:00Z,18.93223819301848,0,0,19484.64527281439,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,196,NA,5,Denominator cohort 196,30 to 39,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
328,9,2435,0,2017-01-20,2021-12-01T00:00:00Z,6.666666666666667,0,0,55333.191811709024,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,197,NA,5,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
329,14,4480,0,2017-01-12,2020-09-19T00:00:00Z,12.265571526351813,0,0,30075.071888730243,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,198,NA,5,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
33,306,83081,0,2017-01-02,2022-06-30T00:00:00Z,227.4633812457221,0,0,1621.746513180047,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,39,NA,5,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
330,35,8474,0,2017-01-04,2022-03-31T00:00:00Z,23.200547570157426,0,0,15899.967201028026,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,199,NA,5,Denominator cohort 199,40 to 49,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
331,18,4490,0,2017-01-27,2022-03-31T00:00:00Z,12.292950034223136,0,0,30008.08954599365,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,200,NA,5,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
332,17,3984,0,2017-01-04,2022-03-31T00:00:00Z,10.907597535934292,0,0,33819.357947166536,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,201,NA,5,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
333,52,13466,0,2017-01-10,2022-03-31T00:00:00Z,36.86789869952088,0,0,10005.667760397406,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,202,NA,5,Denominator cohort 202,50 to 59,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
334,22,5756,0,2017-01-18,2022-03-31T00:00:00Z,15.759069130732374,0,0,23407.97812048497,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,203,NA,5,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
335,30,7710,0,2017-01-10,2022-03-31T00:00:00Z,21.1088295687885,0,0,17475.52815324403,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,204,NA,5,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
336,50,14419,0,2017-01-03,2022-06-30T00:00:00Z,39.47707049965777,0,0,9344.359668597786,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,205,NA,5,Denominator cohort 205,60 to 69,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
337,18,4784,0,2017-02-03,2022-03-31T00:00:00Z,13.097878165639973,0,0,28163.946919212267,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,206,NA,5,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
338,32,9635,0,2017-01-03,2022-06-30T00:00:00Z,26.379192334017795,0,0,13984.05003233124,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,207,NA,5,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
339,30,9329,0,2017-01-04,2022-03-31T00:00:00Z,25.541409993155373,0,0,14442.740064477597,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,208,NA,5,Denominator cohort 208,70 to 79,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
34,8,2126,0,2017-01-26,2022-03-31T00:00:00Z,5.820670773442847,0,0,63375.504262234936,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,43,NA,5,Denominator cohort 43,3 to 12,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
340,11,3186,0,2017-01-17,2022-02-22T00:00:00Z,8.722792607802875,0,0,42290.119918867385,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,209,NA,5,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
341,19,6143,0,2017-01-04,2022-03-31T00:00:00Z,16.8186173853525,0,0,21933.30979350667,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,210,NA,5,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
342,11,3353,0,2017-01-03,2022-03-31T00:00:00Z,9.180013689253936,0,0,40183.812126904704,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,211,NA,5,Denominator cohort 211,80 to 89,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
343,NA,NA,0,2017-06-22,2022-03-31T00:00:00Z,NA,0,0,176819.3202906975,TRUE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,212,NA,5,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
344,8,2591,0,2017-01-03,2021-09-12T00:00:00Z,7.093771389459275,0,0,52001.66810556213,FALSE,FALSE,2,Concomitant_TNF_2,FALSE,overall,TRUE,213,NA,5,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
345,539,339334,0,2017-01-02,2022-06-30T00:00:00Z,929.0458590006845,0,0,397.0610727528379,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,1,NA,5,Denominator cohort 1,0 to 150,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
346,233,144645,0,2017-01-02,2022-06-30T00:00:00Z,396.01642710472277,0,0,931.496574796996,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,2,NA,5,Denominator cohort 2,0 to 150,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
347,306,194689,0,2017-01-02,2022-06-30T00:00:00Z,533.0294318959617,0,0,692.0592435192101,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,3,NA,5,Denominator cohort 3,0 to 150,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
348,8,3585,0,2017-01-26,2022-03-31T00:00:00Z,9.815195071868583,0,0,37583.353434173354,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,7,NA,5,Denominator cohort 7,3 to 12,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
349,NA,NA,0,2018-06-21,2020-12-31T00:00:00Z,NA,0,0,68290.07707121718,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,8,NA,5,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
35,NA,NA,0,2018-06-21,2020-04-30T00:00:00Z,NA,0,0,100624.58705116615,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,44,NA,5,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
350,NA,NA,0,2017-01-26,2022-03-31T00:00:00Z,NA,0,0,83583.32634088802,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,9,NA,5,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
351,16,7397,0,2017-01-09,2020-12-31T00:00:00Z,20.251882272416154,0,0,18214.995547047653,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,10,NA,5,Denominator cohort 10,13 to 17,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
352,11,5256,0,2017-01-09,2020-12-31T00:00:00Z,14.390143737166325,0,0,25634.764471368242,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,11,NA,5,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
353,5,2141,0,2017-01-19,2019-05-31T00:00:00Z,5.861738535249829,0,0,62931.49092083675,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,12,NA,5,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
354,70,29377,0,2017-01-03,2022-06-30T00:00:00Z,80.42984257357973,0,0,4586.456141250349,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,13,NA,5,Denominator cohort 13,18 to 29,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
355,32,14117,0,2017-01-03,2022-03-31T00:00:00Z,38.65023956194388,0,0,9544.260257952219,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,14,NA,5,Denominator cohort 14,18 to 29,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
356,38,15260,0,2017-01-11,2022-06-30T00:00:00Z,41.779603011635864,0,0,8829.378903113466,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,15,NA,5,Denominator cohort 15,18 to 29,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
357,95,42001,0,2017-01-02,2022-06-30T00:00:00Z,114.99247091033538,0,0,3207.9312888148256,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,16,NA,5,Denominator cohort 16,30 to 39,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
358,41,13735,0,2017-01-03,2022-06-30T00:00:00Z,37.60438056125941,0,0,9809.706739098032,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,17,NA,5,Denominator cohort 17,30 to 39,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
359,54,28266,0,2017-01-02,2022-06-30T00:00:00Z,77.38809034907598,0,0,4766.727590090974,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,18,NA,5,Denominator cohort 18,30 to 39,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
36,NA,NA,0,2017-01-26,2022-03-31T00:00:00Z,NA,0,0,171202.44226367408,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,45,NA,5,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
360,83,39407,0,2017-01-02,2022-06-30T00:00:00Z,107.89048596851471,0,0,3419.096151991055,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,19,NA,5,Denominator cohort 19,40 to 49,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
361,33,15995,0,2017-01-02,2022-06-30T00:00:00Z,43.79192334017796,0,0,8423.652520257048,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,20,NA,5,Denominator cohort 20,40 to 49,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
362,50,23412,0,2017-01-12,2022-06-30T00:00:00Z,64.09856262833675,0,0,5755.011193469652,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,21,NA,5,Denominator cohort 21,40 to 49,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
363,84,49184,0,2017-01-04,2022-06-30T00:00:00Z,134.65845311430527,0,0,2739.4340041784217,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,22,NA,5,Denominator cohort 22,50 to 59,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
364,35,19380,0,2017-01-04,2022-03-31T00:00:00Z,53.059548254620125,0,0,6952.338599665195,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,23,NA,5,Denominator cohort 23,50 to 59,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
365,49,29804,0,2017-01-04,2022-06-30T00:00:00Z,81.59890485968515,0,0,4520.746277731562,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,24,NA,5,Denominator cohort 24,50 to 59,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
366,89,40784,0,2017-01-03,2022-06-30T00:00:00Z,111.66050650239562,0,0,3303.656386365032,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,25,NA,5,Denominator cohort 25,60 to 69,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
367,37,17864,0,2017-01-09,2022-06-30T00:00:00Z,48.90896646132786,0,0,7542.337777737993,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,26,NA,5,Denominator cohort 26,60 to 69,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
368,52,22920,0,2017-01-03,2022-06-30T00:00:00Z,62.75154004106776,0,0,5878.54808296298,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,27,NA,5,Denominator cohort 27,60 to 69,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
369,60,48148,0,2017-01-03,2022-06-30T00:00:00Z,131.82203969883642,0,0,2798.3783762879348,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,28,NA,5,Denominator cohort 28,70 to 79,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
37,16,4882,0,2017-01-09,2019-10-23T00:00:00Z,13.366187542778919,0,0,27598.591163767207,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,46,NA,5,Denominator cohort 46,13 to 17,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
370,26,22417,0,2017-01-24,2022-06-30T00:00:00Z,61.374401095140314,0,0,6010.452873333251,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,29,NA,5,Denominator cohort 29,70 to 79,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
371,34,25731,0,2017-01-03,2022-06-30T00:00:00Z,70.44763860369609,0,0,5236.342235494598,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,30,NA,5,Denominator cohort 30,70 to 79,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
372,34,24362,0,2017-01-04,2022-06-30T00:00:00Z,66.69952087611225,0,0,5530.593631947768,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,31,NA,5,Denominator cohort 31,80 to 89,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
373,14,8447,0,2017-01-04,2022-06-30T00:00:00Z,23.12662559890486,0,0,15950.789873506747,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,32,NA,5,Denominator cohort 32,80 to 89,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
374,20,15915,0,2017-01-10,2022-06-30T00:00:00Z,43.572895277207394,0,0,8465.99573116629,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,33,NA,5,Denominator cohort 33,80 to 89,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
375,539,146372,0,2017-01-02,2022-06-30T00:00:00Z,400.7446954140999,0,0,920.5061218095776,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,37,NA,5,Denominator cohort 37,0 to 150,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
376,233,63291,0,2017-01-02,2022-06-30T00:00:00Z,173.28131416837783,0,0,2128.83857201674,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,38,NA,5,Denominator cohort 38,0 to 150,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
377,306,83081,0,2017-01-02,2022-06-30T00:00:00Z,227.4633812457221,0,0,1621.746513180047,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,39,NA,5,Denominator cohort 39,0 to 150,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
378,8,2126,0,2017-01-26,2022-03-31T00:00:00Z,5.820670773442847,0,0,63375.504262234936,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,43,NA,5,Denominator cohort 43,3 to 12,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
379,NA,NA,0,2018-06-21,2020-04-30T00:00:00Z,NA,0,0,100624.58705116615,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,44,NA,5,Denominator cohort 44,3 to 12,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
38,11,3116,0,2017-01-09,2019-10-23T00:00:00Z,8.531143052703628,0,0,43240.15470523475,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,47,NA,5,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
380,NA,NA,0,2017-01-26,2022-03-31T00:00:00Z,NA,0,0,171202.44226367408,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,45,NA,5,Denominator cohort 45,3 to 12,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
381,16,4882,0,2017-01-09,2019-10-23T00:00:00Z,13.366187542778919,0,0,27598.591163767207,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,46,NA,5,Denominator cohort 46,13 to 17,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
382,11,3116,0,2017-01-09,2019-10-23T00:00:00Z,8.531143052703628,0,0,43240.15470523475,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,47,NA,5,Denominator cohort 47,13 to 17,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
383,5,1766,0,2017-01-19,2019-04-16T00:00:00Z,4.8350444900752905,0,0,76294.63310391364,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,48,NA,5,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
384,70,16988,0,2017-01-03,2022-03-31T00:00:00Z,46.510609171800134,0,0,7931.264543295944,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,49,NA,5,Denominator cohort 49,18 to 29,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
385,32,8079,0,2017-01-03,2022-03-31T00:00:00Z,22.119096509240247,0,0,16677.35141249059,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,50,NA,5,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
386,38,8909,0,2017-01-11,2022-03-31T00:00:00Z,24.39151266255989,0,0,15123.619043833369,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,51,NA,5,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
387,95,22431,0,2017-01-02,2022-06-30T00:00:00Z,61.412731006160165,0,0,6006.701531876041,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,52,NA,5,Denominator cohort 52,30 to 39,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
388,41,9528,0,2017-01-03,2022-06-30T00:00:00Z,26.086242299794662,0,0,14141.091736094824,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,53,NA,5,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
389,54,12903,0,2017-01-02,2022-06-30T00:00:00Z,35.3264887063655,0,0,10442.247699101876,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,54,NA,5,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
39,5,1766,0,2017-01-19,2019-04-16T00:00:00Z,4.8350444900752905,0,0,76294.63310391364,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,48,NA,5,Denominator cohort 48,13 to 17,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
390,83,19819,0,2017-01-02,2022-06-30T00:00:00Z,54.261464750171115,0,0,6798.341089939528,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,55,NA,5,Denominator cohort 55,40 to 49,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
391,33,7809,0,2017-01-02,2022-06-30T00:00:00Z,21.37987679671458,0,0,17253.979006468366,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,56,NA,5,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
392,50,12010,0,2017-01-12,2022-06-30T00:00:00Z,32.88158795345654,0,0,11218.67794017581,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,57,NA,5,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
393,84,23572,0,2017-01-04,2022-03-31T00:00:00Z,64.5366187542779,0,0,5715.947822056316,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,58,NA,5,Denominator cohort 58,50 to 59,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
394,35,9282,0,2017-01-04,2022-03-31T00:00:00Z,25.412731006160165,0,0,14515.871801498759,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,59,NA,5,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
395,49,14290,0,2017-01-04,2022-03-31T00:00:00Z,39.123887748117724,0,0,9428.713930126767,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,60,NA,5,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
396,89,24312,0,2017-01-03,2022-06-30T00:00:00Z,66.56262833675565,0,0,5541.967837344171,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,61,NA,5,Denominator cohort 61,60 to 69,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
397,37,10827,0,2017-01-09,2022-06-30T00:00:00Z,29.642710472279262,0,0,12444.474190589404,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,62,NA,5,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
398,52,13485,0,2017-01-03,2022-06-30T00:00:00Z,36.91991786447639,0,0,9991.570045347533,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,63,NA,5,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
399,60,17441,0,2017-01-03,2022-06-30T00:00:00Z,47.75085557837098,0,0,7725.263577863166,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,64,NA,5,Denominator cohort 64,70 to 79,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
4,8,3585,0,2017-01-26,2022-03-31T00:00:00Z,9.815195071868583,0,0,37583.353434173354,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,7,NA,5,Denominator cohort 7,3 to 12,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
40,70,16988,0,2017-01-03,2022-03-31T00:00:00Z,46.510609171800134,0,0,7931.264543295944,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,49,NA,5,Denominator cohort 49,18 to 29,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
400,26,7112,0,2017-01-24,2022-06-30T00:00:00Z,19.471594798083505,0,0,18944.927174003304,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,65,NA,5,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
401,34,10329,0,2017-01-03,2022-03-31T00:00:00Z,28.279260780287473,0,0,13044.469170443557,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,66,NA,5,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
402,34,9335,0,2017-01-04,2022-06-30T00:00:00Z,25.557837097878167,0,0,14433.457103536313,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,67,NA,5,Denominator cohort 67,80 to 89,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
403,14,3400,0,2017-01-04,2022-03-31T00:00:00Z,9.308692676249144,0,0,39628.33001809161,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,68,NA,5,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
404,20,5935,0,2017-01-10,2022-06-30T00:00:00Z,16.249144421629023,0,0,22701.991922748355,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,69,NA,5,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
405,894,569032,0,2017-01-03,2022-06-30T00:00:00Z,1557.924709103354,0,0,236.78162574602393,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,73,NA,5,Denominator cohort 73,0 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
406,387,240226,0,2017-01-03,2022-06-30T00:00:00Z,657.7029431895961,0,0,560.8731863391619,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,74,NA,5,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
407,507,328806,0,2017-01-03,2022-06-30T00:00:00Z,900.2217659137577,0,0,409.77452376632874,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,75,NA,5,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
408,5,1078,0,2017-01-26,2019-12-31T00:00:00Z,2.951403148528405,0,0,124987.31174537243,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,79,NA,5,Denominator cohort 79,3 to 12,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
409,NA,NA,0,2017-01-30,2017-01-31T00:00:00Z,NA,0,0,67368161.03075574,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,80,NA,5,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
41,32,8079,0,2017-01-03,2022-03-31T00:00:00Z,22.119096509240247,0,0,16677.35141249059,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,50,NA,5,Denominator cohort 50,18 to 29,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
410,NA,NA,0,2017-01-26,2019-12-31T00:00:00Z,NA,0,0,125219.63016869097,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,81,NA,5,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
411,13,6984,0,2017-02-16,2022-03-31T00:00:00Z,19.121149897330596,0,0,19292.14233412249,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,82,NA,5,Denominator cohort 82,13 to 17,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
412,5,2738,0,2017-08-03,2021-12-31T00:00:00Z,7.496235455167693,0,0,49209.75970106337,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,83,NA,5,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
413,8,4246,0,2017-02-16,2022-03-31T00:00:00Z,11.624914442162902,0,0,31732.529924990933,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,84,NA,5,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
414,84,38353,0,2017-01-06,2022-06-30T00:00:00Z,105.00479123887749,0,0,3513.0582239071646,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,85,NA,5,Denominator cohort 85,18 to 29,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
415,31,12361,0,2017-01-06,2022-06-30T00:00:00Z,33.842573579739906,0,0,10900.115044212562,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,86,NA,5,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
416,53,25992,0,2017-01-06,2022-06-30T00:00:00Z,71.16221765913758,0,0,5183.76123659247,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,87,NA,5,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
417,109,51587,0,2017-01-12,2022-06-30T00:00:00Z,141.2375085557837,0,0,2611.8270506428266,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,88,NA,5,Denominator cohort 88,30 to 39,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
418,47,19299,0,2017-01-20,2022-06-30T00:00:00Z,52.837782340862425,0,0,6981.518320198534,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,89,NA,5,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
419,62,32288,0,2017-01-12,2022-06-30T00:00:00Z,88.39972621492129,0,0,4172.953483074563,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,90,NA,5,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
42,38,8909,0,2017-01-11,2022-03-31T00:00:00Z,24.39151266255989,0,0,15123.619043833369,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,51,NA,5,Denominator cohort 51,18 to 29,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
420,148,70692,0,2017-01-10,2022-06-30T00:00:00Z,193.5441478439425,0,0,1905.962797226157,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,91,NA,5,Denominator cohort 91,40 to 49,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
421,72,29461,0,2017-01-10,2022-06-30T00:00:00Z,80.65982203969884,0,0,4573.379113455466,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,92,NA,5,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
422,76,41231,0,2017-01-10,2022-06-30T00:00:00Z,112.88432580424367,0,0,3267.8402673112823,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,93,NA,5,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
423,178,83367,0,2017-01-03,2022-06-30T00:00:00Z,228.24640657084188,0,0,1616.1829268356964,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,94,NA,5,Denominator cohort 94,50 to 59,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
424,78,36939,0,2017-01-03,2022-06-30T00:00:00Z,101.13347022587268,0,0,3647.535722718847,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,95,NA,5,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
425,100,46428,0,2017-01-03,2022-06-30T00:00:00Z,127.1129363449692,0,0,2902.048808079424,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,96,NA,5,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
426,186,111914,0,2017-01-07,2022-06-30T00:00:00Z,306.403832991102,0,0,1203.9273197411537,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,97,NA,5,Denominator cohort 97,60 to 69,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
427,83,47998,0,2017-01-09,2022-06-30T00:00:00Z,131.4113620807666,0,0,2807.1236731012023,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,98,NA,5,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
428,103,63916,0,2017-01-07,2022-06-30T00:00:00Z,174.99247091033538,0,0,2108.0218108378417,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,99,NA,5,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
429,114,78936,0,2017-01-04,2022-06-30T00:00:00Z,216.11498973305956,0,0,1706.9058738916526,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,100,NA,5,Denominator cohort 100,70 to 79,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
43,95,22431,0,2017-01-02,2022-06-30T00:00:00Z,61.412731006160165,0,0,6006.701531876041,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,52,NA,5,Denominator cohort 52,30 to 39,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
430,50,37846,0,2017-02-28,2022-06-30T00:00:00Z,103.6167008898015,0,0,3560.120542765721,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,101,NA,5,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
431,64,41090,0,2017-01-04,2022-06-30T00:00:00Z,112.49828884325804,0,0,3279.053834546398,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,102,NA,5,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
432,57,50262,0,2017-01-04,2022-06-30T00:00:00Z,137.6098562628337,0,0,2680.6796797085567,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,103,NA,5,Denominator cohort 103,80 to 89,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
433,20,17590,0,2017-01-04,2022-06-30T00:00:00Z,48.158795345653665,0,0,7659.825017709578,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,104,NA,5,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
434,37,32672,0,2017-01-16,2022-03-31T00:00:00Z,89.45106091718002,0,0,4123.907996495822,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,105,NA,5,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
435,894,250767,0,2017-01-03,2022-06-30T00:00:00Z,686.5626283367557,0,0,537.2968614750405,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,109,NA,5,Denominator cohort 109,0 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
436,387,108405,0,2017-01-03,2022-06-30T00:00:00Z,296.79671457905545,0,0,1242.8976713390664,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,110,NA,5,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
437,507,142362,0,2017-01-03,2022-06-30T00:00:00Z,389.7659137577002,0,0,946.4345967428912,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,111,NA,5,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
438,5,947,0,2017-01-26,2019-12-31T00:00:00Z,2.5927446954141,0,0,142277.00323285267,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,115,NA,5,Denominator cohort 115,3 to 12,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
439,NA,NA,0,2017-01-30,2017-01-31T00:00:00Z,NA,0,0,67368161.03075574,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,116,NA,5,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
44,41,9528,0,2017-01-03,2022-06-30T00:00:00Z,26.086242299794662,0,0,14141.091736094824,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,53,NA,5,Denominator cohort 53,30 to 39,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
440,NA,NA,0,2017-01-26,2019-12-31T00:00:00Z,NA,0,0,142578.11858361005,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,117,NA,5,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
441,13,3816,0,2017-02-16,2022-03-31T00:00:00Z,10.447638603696099,0,0,35308.260498299656,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,118,NA,5,Denominator cohort 118,13 to 17,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
442,5,1333,0,2017-08-03,2019-11-26T00:00:00Z,3.649555099247091,0,0,101077.51092386458,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,119,NA,5,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
443,8,2483,0,2017-02-16,2022-03-31T00:00:00Z,6.798083504449007,0,0,54263.52076581212,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,120,NA,5,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
444,84,21334,0,2017-01-06,2022-06-30T00:00:00Z,58.40930869267625,0,0,6315.567735141628,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,121,NA,5,Denominator cohort 121,18 to 29,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
445,31,7672,0,2017-01-06,2022-06-30T00:00:00Z,21.00479123887748,0,0,17562.08577444102,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,122,NA,5,Denominator cohort 122,18 to 29,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
446,53,13662,0,2017-01-06,2022-03-31T00:00:00Z,37.40451745379877,0,0,9862.122826929548,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,123,NA,5,Denominator cohort 123,18 to 29,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
447,109,29071,0,2017-01-12,2022-06-30T00:00:00Z,79.59206023271732,0,0,4634.732966238226,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,124,NA,5,Denominator cohort 124,30 to 39,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
448,47,12731,0,2017-01-20,2022-05-17T00:00:00Z,34.85557837097878,0,0,10583.325902247387,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,125,NA,5,Denominator cohort 125,30 to 39,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
449,62,16340,0,2017-01-12,2022-06-30T00:00:00Z,44.73648186173853,0,0,8245.796943788953,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,126,NA,5,Denominator cohort 126,30 to 39,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
45,54,12903,0,2017-01-02,2022-06-30T00:00:00Z,35.3264887063655,0,0,10442.247699101876,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,54,NA,5,Denominator cohort 54,30 to 39,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
450,148,37491,0,2017-01-10,2022-06-30T00:00:00Z,102.64476386036961,0,0,3593.8311077728385,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,127,NA,5,Denominator cohort 127,40 to 49,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
451,72,17568,0,2017-01-10,2022-05-04T00:00:00Z,48.09856262833676,0,0,7669.417239384761,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,128,NA,5,Denominator cohort 128,40 to 49,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
452,76,19923,0,2017-01-10,2022-06-30T00:00:00Z,54.54620123203286,0,0,6762.853087462305,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,129,NA,5,Denominator cohort 129,40 to 49,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
453,178,46775,0,2017-01-03,2022-03-31T00:00:00Z,128.06297056810405,0,0,2880.5199799361085,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,130,NA,5,Denominator cohort 130,50 to 59,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
454,78,21549,0,2017-01-03,2022-03-31T00:00:00Z,58.997946611909654,0,0,6252.555666690403,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,131,NA,5,Denominator cohort 131,50 to 59,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
455,100,25226,0,2017-01-03,2022-03-31T00:00:00Z,69.06502395619438,0,0,5341.168717256462,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,132,NA,5,Denominator cohort 132,50 to 59,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
456,186,51975,0,2017-01-07,2022-06-30T00:00:00Z,142.29979466119096,0,0,2592.32942879291,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,133,NA,5,Denominator cohort 133,60 to 69,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
457,83,23444,0,2017-01-09,2022-06-30T00:00:00Z,64.18617385352498,0,0,5747.155863398375,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,134,NA,5,Denominator cohort 134,60 to 69,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
458,103,28531,0,2017-01-07,2022-06-30T00:00:00Z,78.11362080766598,0,0,4722.453543917546,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,135,NA,5,Denominator cohort 135,60 to 69,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
459,114,33028,0,2017-01-04,2022-06-30T00:00:00Z,90.42573579739904,0,0,4079.457492476429,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,136,NA,5,Denominator cohort 136,70 to 79,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
46,83,19819,0,2017-01-02,2022-06-30T00:00:00Z,54.261464750171115,0,0,6798.341089939528,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,55,NA,5,Denominator cohort 55,40 to 49,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
460,50,14690,0,2017-02-28,2022-06-30T00:00:00Z,40.219028062970565,0,0,9171.97563386736,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,137,NA,5,Denominator cohort 137,70 to 79,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
461,64,18338,0,2017-01-04,2022-04-05T00:00:00Z,50.20670773442848,0,0,7347.383687507443,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,138,NA,5,Denominator cohort 138,70 to 79,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
462,57,18196,0,2017-01-04,2022-03-31T00:00:00Z,49.817932922655714,0,0,7404.722030199576,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,139,NA,5,Denominator cohort 139,80 to 89,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
463,20,6083,0,2017-01-04,2022-03-31T00:00:00Z,16.654346338124572,0,0,22149.65018272423,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,140,NA,5,Denominator cohort 140,80 to 89,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
464,37,12113,0,2017-01-16,2022-03-31T00:00:00Z,33.163586584531146,0,0,11123.282594032155,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,141,NA,5,Denominator cohort 141,80 to 89,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
465,209,140123,0,2017-01-03,2022-06-30T00:00:00Z,383.63586584531146,0,0,961.557503489873,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,145,NA,5,Denominator cohort 145,0 to 150,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
466,86,50933,0,2017-01-17,2022-06-30T00:00:00Z,139.4469541409993,0,0,2645.363949924636,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,146,NA,5,Denominator cohort 146,0 to 150,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
467,123,89190,0,2017-01-03,2022-06-30T00:00:00Z,244.18891170431212,0,0,1510.6662412996018,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,147,NA,5,Denominator cohort 147,0 to 150,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
468,NA,NA,0,2020-01-23,2021-10-31T00:00:00Z,NA,0,0,207926.42293443132,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,154,NA,5,Denominator cohort 154,13 to 17,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
469,NA,NA,0,2020-01-23,2021-10-31T00:00:00Z,NA,0,0,207926.42293443132,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,156,NA,5,Denominator cohort 156,13 to 17,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
47,33,7809,0,2017-01-02,2022-06-30T00:00:00Z,21.37987679671458,0,0,17253.979006468366,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,56,NA,5,Denominator cohort 56,40 to 49,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
470,7,2171,0,2017-02-10,2021-12-31T00:00:00Z,5.943874058863792,0,0,62061.87105550966,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,157,NA,5,Denominator cohort 157,18 to 29,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
471,5,1501,0,2017-02-10,2021-12-31T00:00:00Z,4.1095140314852845,0,0,89764.37179314555,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,158,NA,5,Denominator cohort 158,18 to 29,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
472,NA,NA,0,2017-02-21,2018-12-31T00:00:00Z,NA,0,0,201098.9881515097,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,159,NA,5,Denominator cohort 159,18 to 29,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
473,23,13396,0,2017-01-12,2022-03-31T00:00:00Z,36.67624914442163,0,0,10057.951781241525,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,160,NA,5,Denominator cohort 160,30 to 39,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
474,9,3075,0,2017-01-20,2022-03-31T00:00:00Z,8.41889117043121,0,0,43816.69010130455,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,161,NA,5,Denominator cohort 161,30 to 39,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
475,14,10321,0,2017-01-12,2022-03-31T00:00:00Z,28.257357973990416,0,0,13054.580182299342,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,162,NA,5,Denominator cohort 162,30 to 39,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
476,35,17195,0,2017-01-04,2022-06-30T00:00:00Z,47.07734428473648,0,0,7835.784941059115,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,163,NA,5,Denominator cohort 163,40 to 49,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
477,18,9370,0,2017-01-27,2022-06-30T00:00:00Z,25.65366187542779,0,0,14379.54344306419,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,164,NA,5,Denominator cohort 164,40 to 49,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
478,17,7825,0,2017-01-04,2022-06-30T00:00:00Z,21.423682409308693,0,0,17218.699304985494,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,165,NA,5,Denominator cohort 165,40 to 49,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
479,52,25593,0,2017-01-10,2022-06-30T00:00:00Z,70.06981519507187,0,0,5264.57711333222,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,166,NA,5,Denominator cohort 166,50 to 59,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
48,50,12010,0,2017-01-12,2022-06-30T00:00:00Z,32.88158795345654,0,0,11218.67794017581,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,57,NA,5,Denominator cohort 57,40 to 49,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
480,22,9902,0,2017-01-18,2022-06-30T00:00:00Z,27.110198494182068,0,0,13606.980616189809,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,167,NA,5,Denominator cohort 167,50 to 59,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
481,30,15691,0,2017-01-10,2022-03-31T00:00:00Z,42.959616700889804,0,0,8586.85374173166,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,168,NA,5,Denominator cohort 168,50 to 59,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
482,50,27546,0,2017-01-03,2022-06-30T00:00:00Z,75.41683778234086,0,0,4891.320774759002,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,169,NA,5,Denominator cohort 169,60 to 69,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
483,18,7358,0,2017-02-03,2022-03-31T00:00:00Z,20.145106091718002,0,0,18311.54145984119,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,170,NA,5,Denominator cohort 170,60 to 69,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
484,32,20188,0,2017-01-03,2022-06-30T00:00:00Z,55.27173169062286,0,0,6674.079753393675,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,171,NA,5,Denominator cohort 171,60 to 69,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
485,30,25132,0,2017-01-04,2022-06-30T00:00:00Z,68.80766598220397,0,0,5361.146031414591,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,172,NA,5,Denominator cohort 172,70 to 79,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
486,11,9058,0,2017-01-17,2022-06-30T00:00:00Z,24.799452429842574,0,0,14874.842356095327,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,173,NA,5,Denominator cohort 173,70 to 79,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
487,19,16074,0,2017-01-04,2022-03-31T00:00:00Z,44.0082135523614,0,0,8382.252212362293,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,174,NA,5,Denominator cohort 174,70 to 79,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
488,11,11928,0,2017-01-03,2022-03-31T00:00:00Z,32.6570841889117,0,0,11295.801648349388,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,175,NA,5,Denominator cohort 175,80 to 89,Both,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
489,NA,NA,0,2017-06-22,2022-03-31T00:00:00Z,NA,0,0,50143.77449256103,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,176,NA,5,Denominator cohort 176,80 to 89,Male,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
49,84,23572,0,2017-01-04,2022-03-31T00:00:00Z,64.5366187542779,0,0,5715.947822056316,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,58,NA,5,Denominator cohort 58,50 to 59,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
490,8,9241,0,2017-01-03,2022-03-31T00:00:00Z,25.300479123887747,0,0,14580.27508511108,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,177,NA,5,Denominator cohort 177,80 to 89,Female,0,2002-01-01,2022-12-31,5,Psoriatic_arthritis,PHARMETRICS_100k,Incidence estimates
491,209,60743,0,2017-01-03,2022-06-30T00:00:00Z,166.30527036276524,0,0,2218.137432486237,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,181,NA,5,Denominator cohort 181,0 to 150,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
492,86,24309,0,2017-01-17,2022-03-31T00:00:00Z,66.55441478439425,0,0,5542.651777593133,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,182,NA,5,Denominator cohort 182,0 to 150,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
493,123,36434,0,2017-01-03,2022-06-30T00:00:00Z,99.75085557837097,0,0,3698.093046646306,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,183,NA,5,Denominator cohort 183,0 to 150,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
494,NA,NA,0,2020-01-23,2021-01-22T00:00:00Z,NA,0,0,368132.0274904686,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,190,NA,5,Denominator cohort 190,13 to 17,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
495,NA,NA,0,2020-01-23,2021-01-22T00:00:00Z,NA,0,0,368132.0274904686,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,192,NA,5,Denominator cohort 192,13 to 17,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
496,7,1217,0,2017-02-10,2021-12-31T00:00:00Z,3.3319644079397674,0,0,110711.85050247452,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,193,NA,5,Denominator cohort 193,18 to 29,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
497,5,812,0,2017-02-10,2021-12-31T00:00:00Z,2.223134839151266,0,0,165931.43111023583,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,194,NA,5,Denominator cohort 194,18 to 29,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
498,NA,NA,0,2017-02-21,2018-04-10T00:00:00Z,NA,0,0,332682.2766950901,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,195,NA,5,Denominator cohort 195,18 to 29,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
499,23,6915,0,2017-01-12,2021-12-01T00:00:00Z,18.93223819301848,0,0,19484.64527281439,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,196,NA,5,Denominator cohort 196,30 to 39,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
5,NA,NA,0,2018-06-21,2020-12-31T00:00:00Z,NA,0,0,68290.07707121718,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,8,NA,5,Denominator cohort 8,3 to 12,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
50,35,9282,0,2017-01-04,2022-03-31T00:00:00Z,25.412731006160165,0,0,14515.871801498759,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,59,NA,5,Denominator cohort 59,50 to 59,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
500,9,2435,0,2017-01-20,2021-12-01T00:00:00Z,6.666666666666667,0,0,55333.191811709024,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,197,NA,5,Denominator cohort 197,30 to 39,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
501,14,4480,0,2017-01-12,2020-09-19T00:00:00Z,12.265571526351813,0,0,30075.071888730243,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,198,NA,5,Denominator cohort 198,30 to 39,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
502,35,8474,0,2017-01-04,2022-03-31T00:00:00Z,23.200547570157426,0,0,15899.967201028026,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,199,NA,5,Denominator cohort 199,40 to 49,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
503,18,4490,0,2017-01-27,2022-03-31T00:00:00Z,12.292950034223136,0,0,30008.08954599365,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,200,NA,5,Denominator cohort 200,40 to 49,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
504,17,3984,0,2017-01-04,2022-03-31T00:00:00Z,10.907597535934292,0,0,33819.357947166536,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,201,NA,5,Denominator cohort 201,40 to 49,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
505,52,13466,0,2017-01-10,2022-03-31T00:00:00Z,36.86789869952088,0,0,10005.667760397406,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,202,NA,5,Denominator cohort 202,50 to 59,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
506,22,5756,0,2017-01-18,2022-03-31T00:00:00Z,15.759069130732374,0,0,23407.97812048497,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,203,NA,5,Denominator cohort 203,50 to 59,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
507,30,7710,0,2017-01-10,2022-03-31T00:00:00Z,21.1088295687885,0,0,17475.52815324403,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,204,NA,5,Denominator cohort 204,50 to 59,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
508,50,14419,0,2017-01-03,2022-06-30T00:00:00Z,39.47707049965777,0,0,9344.359668597786,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,205,NA,5,Denominator cohort 205,60 to 69,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
509,18,4784,0,2017-02-03,2022-03-31T00:00:00Z,13.097878165639973,0,0,28163.946919212267,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,206,NA,5,Denominator cohort 206,60 to 69,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
51,49,14290,0,2017-01-04,2022-03-31T00:00:00Z,39.123887748117724,0,0,9428.713930126767,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,60,NA,5,Denominator cohort 60,50 to 59,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
510,32,9635,0,2017-01-03,2022-06-30T00:00:00Z,26.379192334017795,0,0,13984.05003233124,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,207,NA,5,Denominator cohort 207,60 to 69,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
511,30,9329,0,2017-01-04,2022-03-31T00:00:00Z,25.541409993155373,0,0,14442.740064477597,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,208,NA,5,Denominator cohort 208,70 to 79,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
512,11,3186,0,2017-01-17,2022-02-22T00:00:00Z,8.722792607802875,0,0,42290.119918867385,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,209,NA,5,Denominator cohort 209,70 to 79,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
513,19,6143,0,2017-01-04,2022-03-31T00:00:00Z,16.8186173853525,0,0,21933.30979350667,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,210,NA,5,Denominator cohort 210,70 to 79,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
514,11,3353,0,2017-01-03,2022-03-31T00:00:00Z,9.180013689253936,0,0,40183.812126904704,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,211,NA,5,Denominator cohort 211,80 to 89,Both,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
515,NA,NA,0,2017-06-22,2022-03-31T00:00:00Z,NA,0,0,176819.3202906975,TRUE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,212,NA,5,Denominator cohort 212,80 to 89,Male,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
516,8,2591,0,2017-01-03,2021-09-12T00:00:00Z,7.093771389459275,0,0,52001.66810556213,FALSE,FALSE,3,Concomitant_TNF_3,FALSE,overall,TRUE,213,NA,5,Denominator cohort 213,80 to 89,Female,0,2002-01-01,2022-12-31,6,Psoriatic_arthritis_365,PHARMETRICS_100k,Incidence estimates
52,89,24312,0,2017-01-03,2022-06-30T00:00:00Z,66.56262833675565,0,0,5541.967837344171,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,61,NA,5,Denominator cohort 61,60 to 69,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
53,37,10827,0,2017-01-09,2022-06-30T00:00:00Z,29.642710472279262,0,0,12444.474190589404,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,62,NA,5,Denominator cohort 62,60 to 69,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
54,52,13485,0,2017-01-03,2022-06-30T00:00:00Z,36.91991786447639,0,0,9991.570045347533,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,63,NA,5,Denominator cohort 63,60 to 69,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
55,60,17441,0,2017-01-03,2022-06-30T00:00:00Z,47.75085557837098,0,0,7725.263577863166,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,64,NA,5,Denominator cohort 64,70 to 79,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
56,26,7112,0,2017-01-24,2022-06-30T00:00:00Z,19.471594798083505,0,0,18944.927174003304,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,65,NA,5,Denominator cohort 65,70 to 79,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
57,34,10329,0,2017-01-03,2022-03-31T00:00:00Z,28.279260780287473,0,0,13044.469170443557,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,66,NA,5,Denominator cohort 66,70 to 79,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
58,34,9335,0,2017-01-04,2022-06-30T00:00:00Z,25.557837097878167,0,0,14433.457103536313,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,67,NA,5,Denominator cohort 67,80 to 89,Both,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
59,14,3400,0,2017-01-04,2022-03-31T00:00:00Z,9.308692676249144,0,0,39628.33001809161,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,68,NA,5,Denominator cohort 68,80 to 89,Male,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
6,NA,NA,0,2017-01-26,2022-03-31T00:00:00Z,NA,0,0,83583.32634088802,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,9,NA,5,Denominator cohort 9,3 to 12,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
60,20,5935,0,2017-01-10,2022-06-30T00:00:00Z,16.249144421629023,0,0,22701.991922748355,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,69,NA,5,Denominator cohort 69,80 to 89,Female,0,2002-01-01,2022-12-31,2,IBD_365,PHARMETRICS_100k,Incidence estimates
61,894,569032,0,2017-01-03,2022-06-30T00:00:00Z,1557.924709103354,0,0,236.78162574602393,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,73,NA,5,Denominator cohort 73,0 to 150,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
62,387,240226,0,2017-01-03,2022-06-30T00:00:00Z,657.7029431895961,0,0,560.8731863391619,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,74,NA,5,Denominator cohort 74,0 to 150,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
63,507,328806,0,2017-01-03,2022-06-30T00:00:00Z,900.2217659137577,0,0,409.77452376632874,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,75,NA,5,Denominator cohort 75,0 to 150,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
64,5,1078,0,2017-01-26,2019-12-31T00:00:00Z,2.951403148528405,0,0,124987.31174537243,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,79,NA,5,Denominator cohort 79,3 to 12,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
65,NA,NA,0,2017-01-30,2017-01-31T00:00:00Z,NA,0,0,67368161.03075574,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,80,NA,5,Denominator cohort 80,3 to 12,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
66,NA,NA,0,2017-01-26,2019-12-31T00:00:00Z,NA,0,0,125219.63016869097,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,81,NA,5,Denominator cohort 81,3 to 12,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
67,13,6984,0,2017-02-16,2022-03-31T00:00:00Z,19.121149897330596,0,0,19292.14233412249,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,82,NA,5,Denominator cohort 82,13 to 17,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
68,5,2738,0,2017-08-03,2021-12-31T00:00:00Z,7.496235455167693,0,0,49209.75970106337,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,83,NA,5,Denominator cohort 83,13 to 17,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
69,8,4246,0,2017-02-16,2022-03-31T00:00:00Z,11.624914442162902,0,0,31732.529924990933,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,84,NA,5,Denominator cohort 84,13 to 17,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
7,16,7397,0,2017-01-09,2020-12-31T00:00:00Z,20.251882272416154,0,0,18214.995547047653,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,10,NA,5,Denominator cohort 10,13 to 17,Both,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
70,84,38353,0,2017-01-06,2022-06-30T00:00:00Z,105.00479123887749,0,0,3513.0582239071646,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,85,NA,5,Denominator cohort 85,18 to 29,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
71,31,12361,0,2017-01-06,2022-06-30T00:00:00Z,33.842573579739906,0,0,10900.115044212562,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,86,NA,5,Denominator cohort 86,18 to 29,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
72,53,25992,0,2017-01-06,2022-06-30T00:00:00Z,71.16221765913758,0,0,5183.76123659247,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,87,NA,5,Denominator cohort 87,18 to 29,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
73,109,51587,0,2017-01-12,2022-06-30T00:00:00Z,141.2375085557837,0,0,2611.8270506428266,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,88,NA,5,Denominator cohort 88,30 to 39,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
74,47,19299,0,2017-01-20,2022-06-30T00:00:00Z,52.837782340862425,0,0,6981.518320198534,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,89,NA,5,Denominator cohort 89,30 to 39,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
75,62,32288,0,2017-01-12,2022-06-30T00:00:00Z,88.39972621492129,0,0,4172.953483074563,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,90,NA,5,Denominator cohort 90,30 to 39,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
76,148,70692,0,2017-01-10,2022-06-30T00:00:00Z,193.5441478439425,0,0,1905.962797226157,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,91,NA,5,Denominator cohort 91,40 to 49,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
77,72,29461,0,2017-01-10,2022-06-30T00:00:00Z,80.65982203969884,0,0,4573.379113455466,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,92,NA,5,Denominator cohort 92,40 to 49,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
78,76,41231,0,2017-01-10,2022-06-30T00:00:00Z,112.88432580424367,0,0,3267.8402673112823,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,93,NA,5,Denominator cohort 93,40 to 49,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
79,178,83367,0,2017-01-03,2022-06-30T00:00:00Z,228.24640657084188,0,0,1616.1829268356964,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,94,NA,5,Denominator cohort 94,50 to 59,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
8,11,5256,0,2017-01-09,2020-12-31T00:00:00Z,14.390143737166325,0,0,25634.764471368242,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,11,NA,5,Denominator cohort 11,13 to 17,Male,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
80,78,36939,0,2017-01-03,2022-06-30T00:00:00Z,101.13347022587268,0,0,3647.535722718847,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,95,NA,5,Denominator cohort 95,50 to 59,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
81,100,46428,0,2017-01-03,2022-06-30T00:00:00Z,127.1129363449692,0,0,2902.048808079424,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,96,NA,5,Denominator cohort 96,50 to 59,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
82,186,111914,0,2017-01-07,2022-06-30T00:00:00Z,306.403832991102,0,0,1203.9273197411537,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,97,NA,5,Denominator cohort 97,60 to 69,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
83,83,47998,0,2017-01-09,2022-06-30T00:00:00Z,131.4113620807666,0,0,2807.1236731012023,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,98,NA,5,Denominator cohort 98,60 to 69,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
84,103,63916,0,2017-01-07,2022-06-30T00:00:00Z,174.99247091033538,0,0,2108.0218108378417,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,99,NA,5,Denominator cohort 99,60 to 69,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
85,114,78936,0,2017-01-04,2022-06-30T00:00:00Z,216.11498973305956,0,0,1706.9058738916526,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,100,NA,5,Denominator cohort 100,70 to 79,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
86,50,37846,0,2017-02-28,2022-06-30T00:00:00Z,103.6167008898015,0,0,3560.120542765721,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,101,NA,5,Denominator cohort 101,70 to 79,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
87,64,41090,0,2017-01-04,2022-06-30T00:00:00Z,112.49828884325804,0,0,3279.053834546398,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,102,NA,5,Denominator cohort 102,70 to 79,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
88,57,50262,0,2017-01-04,2022-06-30T00:00:00Z,137.6098562628337,0,0,2680.6796797085567,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,103,NA,5,Denominator cohort 103,80 to 89,Both,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
89,20,17590,0,2017-01-04,2022-06-30T00:00:00Z,48.158795345653665,0,0,7659.825017709578,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,104,NA,5,Denominator cohort 104,80 to 89,Male,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
9,5,2141,0,2017-01-19,2019-05-31T00:00:00Z,5.861738535249829,0,0,62931.49092083675,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,12,NA,5,Denominator cohort 12,13 to 17,Female,0,2002-01-01,2022-12-31,1,IBD,PHARMETRICS_100k,Incidence estimates
90,37,32672,0,2017-01-16,2022-03-31T00:00:00Z,89.45106091718002,0,0,4123.907996495822,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,105,NA,5,Denominator cohort 105,80 to 89,Female,0,2002-01-01,2022-12-31,3,Plaque_psoriasis,PHARMETRICS_100k,Incidence estimates
91,894,250767,0,2017-01-03,2022-06-30T00:00:00Z,686.5626283367557,0,0,537.2968614750405,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,109,NA,5,Denominator cohort 109,0 to 150,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
92,387,108405,0,2017-01-03,2022-06-30T00:00:00Z,296.79671457905545,0,0,1242.8976713390664,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,110,NA,5,Denominator cohort 110,0 to 150,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
93,507,142362,0,2017-01-03,2022-06-30T00:00:00Z,389.7659137577002,0,0,946.4345967428912,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,111,NA,5,Denominator cohort 111,0 to 150,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
94,5,947,0,2017-01-26,2019-12-31T00:00:00Z,2.5927446954141,0,0,142277.00323285267,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,115,NA,5,Denominator cohort 115,3 to 12,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
95,NA,NA,0,2017-01-30,2017-01-31T00:00:00Z,NA,0,0,67368161.03075574,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,116,NA,5,Denominator cohort 116,3 to 12,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
96,NA,NA,0,2017-01-26,2019-12-31T00:00:00Z,NA,0,0,142578.11858361005,TRUE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,117,NA,5,Denominator cohort 117,3 to 12,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
97,13,3816,0,2017-02-16,2022-03-31T00:00:00Z,10.447638603696099,0,0,35308.260498299656,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,118,NA,5,Denominator cohort 118,13 to 17,Both,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
98,5,1333,0,2017-08-03,2019-11-26T00:00:00Z,3.649555099247091,0,0,101077.51092386458,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,119,NA,5,Denominator cohort 119,13 to 17,Male,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
99,8,2483,0,2017-02-16,2022-03-31T00:00:00Z,6.798083504449007,0,0,54263.52076581212,FALSE,FALSE,1,Concomitant_TNF_1,FALSE,overall,TRUE,120,NA,5,Denominator cohort 120,13 to 17,Female,0,2002-01-01,2022-12-31,4,Plaque_psoriasis_365,PHARMETRICS_100k,Incidence estimates
